Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07738614
PHASE1

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight

Sponsor: Eli Lilly and Company

View on ClinicalTrials.gov

Summary

The main purpose of this study is to find out how significantly Eloralintide slows stomach emptying in participants who are overweight or obese. For each participant, the study will last approximately 21 weeks and will include 2 overnight stays in the clinical research unit (CRU) lasting between 4 and 8 days. There will be 13 other visits.

Official title: A Phase 1, Investigator- and Participant-Blinded, Placebo-Controlled, Randomized, Multiple-Dose Study to Evaluate the Gastric Emptying Delay, Pharmacokinetics, Safety, and Tolerability of Eloralintide in Participants With Obesity or Overweight

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

56

Start Date

2026-07-31

Completion Date

2026-12

Last Updated

2026-08-20

Healthy Volunteers

Yes

Interventions

DRUG

Eloralintide

Administered SC

DRUG

Placebo

Administered SC

DRUG

Acetaminophen

Administered Oral Solution

Locations (2)

ICON Early Phase Services

San Antonio, Texas, United States

Lilly Centre for Clinical Pharmacology

Singapore, Singapore